Oprelvekin
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Oprelvekin?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Oprelvekin is recombinant interleukin eleven (IL-11),[1] a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega.
This article needs additional citations for verification. (March 2024) |
Quick Facts Clinical data, AHFS/Drugs.com ...
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
Routes of administration | subcutaneous (s.c.) injection |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | >80% (s.c.) |
Metabolism | mainly renal |
Elimination half-life | 6.9 ± 1.7 hours |
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C854H1411N253O235S2 |
Molar mass | 19047.34 g·mol−1 |
![]() ![]() |
Close